Nafarelin vs Triptorelin
Research Verdict
Neither compound has a universal evidence advantage. Both peptides serve distinct research goals with comparable evidence; choose by target mechanism.
Quick Answers
Which is better, Nafarelin or Triptorelin?
Neither compound has a universal evidence advantage. Both peptides serve distinct research goals with comparable evidence; choose by target mechanism.
What is the key difference between Nafarelin and Triptorelin?
Nafarelin requires twice-daily intranasal administration; triptorelin offers monthly to 6-monthly depot injections - a fundamental adherence and pharmacokinetic difference.
Evidence Comparison
Both: FDA approved with extensive Phase 3 data. Nafarelin (Synarel): approved for endometriosis and central precocious puberty, intranasal delivery. Triptorelin (Trelstar): approved for prostate cancer and central precocious puberty, IM depot formulations (1-month, 3-month, 6-month). Evidence quality is comparable; route and indication differ.
Evidence Context Favoring Nafarelin
When non-injectable administration is preferred, particularly in endometriosis or pediatric settings where intranasal delivery improves compliance.
Evidence Context Favoring Triptorelin
When long-acting depot suppression is needed, particularly in prostate cancer where sustained gonadal suppression and infrequent dosing are critical.
Side-by-Side Snapshot
| Evidence grade | Nafarelin: Level A Triptorelin: Level A |
|---|---|
| Research status | Nafarelin: FDA Approved Triptorelin: FDA Approved |
| Primary category | Nafarelin: Sexual Health Triptorelin: Sexual Health |
| Cited studies | Nafarelin: 3 Triptorelin: 3 |